Beylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) -tumor barrier (BTB), which limit the efficacy of systemic
therapies. Recent advances in molecular biology
of the potential of immune system-derived miRNAs to revolutionize CVD management and
therapy, addressing a major
the influence of two-dimensional discrete breathers (DBs) excited using four one-
component DNVMs
the potential of stromal vascular fraction (SVF) cell
therapy as a novel regenerative treatment for ICH. SVF
Valeeva, Diana,
Akhiiarova, Karina,
Minniakhmetov, Ildar,
Mokrysheva, Natalia,
Khusainova, Rita,
Tyurin, Anton (2025) characterized by fragility of bones and recurrent fractures. In addition to the hereditary
componentSangeet, Ghai,,
Ni, Tiffany T.,
Pavlovich, Christian P.,
Futterer, Jurgen J.,
Schade, George R.,
Sanchez-Salas, Rafael,
Cornud, Francois,
Eggener, Scott,
Feller, John F.,
George, Arvin K.,
Villers, Arnauld,
de la Rosette, Jean (2025) -related morbidities associated with conventional
therapies. Focal
therapy (FT) is emerging as a promising alternative